Compare iShares Global Clean Energy ETF (ICLN) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Novo Nordisk A/S — how do they compare? iShares Global Clean Energy ETF trades at $18.56, while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares Global Clean Energy ETF pays none, and iShares Global Clean Energy ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| ICLN | NVO | |
|---|---|---|
52-Week High | $23.75 | $71.70 |
52-Week Low | $13.41 | $35.29 |
Market Cap | — | $220.53B |
Sector | — | Health |
Enterprise Value | — | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $18.52, up 0.82% today, while technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF holds 105 global clean energy companies, benefiting from AI-driven electricity demand and high oil prices, yet faces policy risks. Recent news highlights its 29% YTD return outperforming the S&P 500, with a P/E of 25.7x and long-term EPS growth of 9.1% as of Seeking Alpha on June 7, 2026.
Outlook is mixed: bullish momentum from energy transition trends supports growth, but regulatory uncertainties and high valuation pose risks. Investors may see opportunity in the clean energy sector's structural shift, though volatility from policy changes requires caution.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
